Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ward, J. A.
Right arrow Articles by Morris, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, J. A.
Right arrow Articles by Morris, I. D.

Journal of Andrology, Vol 10, Issue 6 478-486, Copyright © 1989 by The American Society of Andrology

JOURNAL ARTICLE

Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist

J. A. Ward, B. J. Furr, B. Valcaccia, B. Curry, C. W. Bardin, G. L. Gunsalus and I. D. Morris
Department of Physiological Sciences, University of Manchester Medical School, United Kingdom.

A sustained-release formulation of a potent gonadotropin-releasing hormone (GnRH) agonist, Zoladex (D-Ser(But),6 Aza Gly10-GnRH; ICI 118,630; goserelin), was administered subcutaneously (3.6 mg/depot) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis function could be suppressed and whether suppression was maintained throughout the period of treatment. Administration of Zoladex resulted in sustained decreases in weight of the testis, epididymis, seminal vesicles and prostate gland. The decreases were apparent within 2 wk of initiating treatment. Patchy degeneration of the seminiferous tubules and atrophy of the Leydig cells were observed, but did not progress beyond the degree observed after 1 month of treatment. Serum and testis testosterone were markedly depressed after 2 wk of treatment, as was testis [125I]hCG binding. Serum gonadotropins were also reduced by treatment. Serum androgen binding protein (ABP) was elevated, testis ABP content remained unchanged, and epididymal ABP content was reduced. The changes are consistent with the hypothesis that this compound affects both the anterior pituitary gland and the testis. These findings indicate that depot delivery systems are a convenient way to administer GnRH analogs for sustained treatment schedules.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. L. Thompson, K. G. Murphy, M. Patterson, G. A. Bewick, G. W. H. Stamp, A. E. Curtis, J. H. Cooke, P. H. Jethwa, J. F. Todd, M. A. Ghatei, et al.
Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1074 - E1082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Meistrich, G. Wilson, and I. Huhtaniemi
Hormonal Treatment after Cytotoxic Therapy Stimulates Recovery of Spermatogenesis
Cancer Res., August 1, 1999; 59(15): 3557 - 3560.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by The American Society of Andrology.